RxDoctor Payments Data

Michael Scammahorn, APRN

Psychiatric/Mental Health · Tulsa, OKNPI 1285096909

Payments from drug & device makers

$2,336in general payments, 2019–2025

Across 31 payments — averaging $75.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$456
  • Pear Therapeutics (US), Inc.$193
  • Alkermes, Inc.$135
  • E.r. Squibb & Sons, L.L.C.$122
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$2,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,336 in reported general payments places this provider in the 65th percentile of 231 psychiatric/mental health providers in Oklahoma.

See all psychiatric/mental health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$5,636
Medicare patients
22
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil24$76,290
TrintellixVortioxetine Hydrobromide14$6,776
Aripiprazole31$4,064
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl36$2,729
Duloxetine Hcl54$993
Gabapentin27$974
Quetiapine Fumarate36$889
Buspirone Hcl54$811
Trazodone Hcl64$712
Escitalopram Oxalate13$439
Fluoxetine Hcl21$405
Eszopiclone31$391
Hydroxyzine Pamoate21$377
Prazosin Hcl13$316
Benztropine Mesylate15$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$135$76,29024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 231 psychiatric/mental health providers in Oklahoma.

Other psychiatric/mental health in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →